Archives202520242023202220212020201920182017201620152014201320122011 August 17, 2021Lanstead Capital TR1 Read More August 12, 2021FDA approves the Lupzuor™ PK study Read More July 30, 2021BOARD CHANGES Read More July 16, 2021BOARD APPOINTMENT Read More June 28, 20212021 RESULT OF ANNUAL GENERAL MEETING – ALL RESOLUTIONS PASSED Read More June 24, 2021FDA to agree on the Lupzuor™ PK study via a written response to “Type Read More June 02, 2021Notice of AGM and posting of Report & Accounts Read More May 24, 2021Director Retirement Read More April 29, 2021FINAL RESULTS ANNOUNCEMENT for the twelve months ended 31 December 2020 Read More February 09, 2021Lupuzor™ scheduled to commence international Phase 3 trial in Lupus patients in H2 2021 Read More January 18, 2021Appointment of Company Secretary Read More January 04, 2021Lanstead Capital TR1 Read More 1…678910…16
February 09, 2021Lupuzor™ scheduled to commence international Phase 3 trial in Lupus patients in H2 2021 Read More
